Feature | Lung Cancer | October 26, 2015

New Data May Help Physicians Better Understand Risk of Lung Cancer

Researchers confirm predictive capabilities of minimally invasive procedure that offers high accuracy for positive and negative diagnosis

University of Missouri, EBUS-TBFNA, lung cancer diagnosis

October 26, 2015 — University of Missouri researchers have developed a new scoring system for a common lung cancer diagnostic test that may help physicians better understand the risk for malignancy when evaluating patients.

Endobronchial ultrasound-guided transbronchial fine-needle aspiration, or EBUS-TBFNA, is a minimally invasive procedure often used for the initial diagnosis of many lung cancers. The test uses a thin, flexible scope that passes through the mouth and into the lungs to remove a small piece of tissue for evaluation. The test is commonly used because it can provide a rapid cancer diagnosis without the need for an invasive open procedure.

“The EBUS-TBFNA procedure is a diagnostic tool for lung cancer that yields proven results,” said Lester Layfield, M.D., professor and chair of the Department of Pathology and Anatomical Sciences at the MU School of Medicine and lead author of the study. “The test categorizes the results as ‘benign,’ ‘non-diagnostic,’ ‘atypical,’ ‘suspicious for malignancy’ or ‘malignant.’ Our goal with this study was to understand the risk of cancer associated with each category.”

Layfield’s research team evaluated information from 136 patients who received a diagnosis following the EBUS-TBFNA procedure. The same patients then had an open surgical procedure to confirm whether the tissue was cancerous or benign.

Layfield’s research team found that the EBUS-TBFNA tool provided an accurate positive diagnosis of lung cancer 84 percent of the time and an accurate negative diagnosis of lung cancer 68 percent of the time. The study also provided the research team with an estimation of malignancy risks for each category, which in the future could help doctors offer patients enhanced care and counseling, Layfield said.

The study, “Malignancy Risk Associated with the EBUS-FNA Diagnostic Categories Nondiagnostic, Benign, Atypical, Suspicious for Malignancy, and Malignant for Mediastinal Lymph Node Aspirate Specimens,” recently was published in the Journal of the American Society of Cytopathology.

For more information: www.jascyto.org

Related Content

Patients whose cancer has not spread far past the lungs may benefit from targeting tumor sites with radiation or surgery after initial treatment, according to ASTRO study
News | ASTRO | October 21, 2018
Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Adherence to Annual Lung Cancer Screening Needs Improvement
News | Lung Cancer | October 03, 2018
A study of adherence to annual low-dose computed tomography (LDCT) screening within the Veteran Health Administration...
Augusta University Streamlines Lung Cancer Diagnosis With Hybrid Operating Room

Carsten Schroeder, M.D., thoracic surgical oncologist at the Georgia Cancer Center and Medical College of Georgia at Augusta University in the hybrid OR. Image courtesy of Phil Jones, Senior Photographer, Augusta University

News | Lung Cancer | September 26, 2018
September 26, 2018 — When it comes to surviving cancer, early detection and treatment could be the key to a patient's
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
RSNA Announces Pneumonia Detection Machine Learning Challenge
News | Artificial Intelligence | August 27, 2018
The Radiological Society of North America (RSNA) has launched its second annual machine learning challenge. The RSNA...
Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Metro Health-University of Michigan Health Partners With Eon to Improve Lung Cancer Care
News | Oncology Diagnostics | August 07, 2018
Metro Health-University of Michigan Health announced it is partnering with healthcare data company Eon to improve the...
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...